Item 8.01 Other Events.

On November 26, 2021, Ocugen, Inc. (the "Company") issued a press release providing an Update on its Investigational New Drug Application with U.S. FDA to initiate a phase 3 clinical trial evaluating COVID-19 vaccine candidate COVAXIN™ (BBV152). A copy of this press release is filed herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.




Item 9.01    Financial Statements and Exhibits.

The following exhibits are being filed herewith:





(d) Exhibits



Exhibit No.    Document

  99.1           Press Release of Ocugen, Inc. dated November 26, 2021.
               Cover Page Interactive Data File (embedded within the Inline XBRL
104            document).




                                       1

© Edgar Online, source Glimpses